Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer

被引:40
作者
Kefeli, U.
Dane, F.
Yumuk, P. F. [1 ]
Karamanoglu, A. [2 ]
Iyikesici, S.
Basaran, G.
Turhal, N. S.
机构
[1] Marmara Univ, Sch Med, Dept Internal Med, Div Med Oncol, Istanbul, Turkey
[2] Marmara Univ, Med Sch Hosp, Gul Genc Outpatient Therapy Ctr, Istanbul, Turkey
关键词
catheters; indwelling; catheterization; central venous; neoplasms; heparin; venous thrombosis; CENTRAL VENOUS CATHETERS; MOLECULAR-WEIGHT HEPARIN; ACCESS DEVICES; PREVENTION; COMPLICATIONS; THROMBOSIS; TRIAL; UROKINASE; WARFARIN; CHILDREN;
D O I
10.1111/j.1365-2354.2008.00973.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The long-term use of subcutaneous implanted ports for chemotherapy in cancer patients has been associated with the occurrence of thrombosis and infection. In this study, we compared the safety and efficacy of administration of 1000 U of heparin flushes in prolonged interval (every 6 weeks) with standard dose and schedule (500 U every 4 weeks) for port-related infections and thrombosis during periods of non-use. Data were collected retrospectively from patients treated for various cancer types (matched as 2: 1 for age, gender, stage of the disease). Patients who had diseases that could cause thrombosis or bleeding in their past medical history, or were taking oral anticoagulants, or had contraindications for heparin usage were excluded. After completing their chemotherapy, 59 patients received prolonged interval, while 30 patients received standard schedule. All patients were followed for at least 1 year. No clinically documented port-related infection or thrombosis has been found in both groups. Also, none of the devices was removed during this time. Prophylactic flushing of central venous ports with 1000 U of heparin in every 6 weeks might be a safe, easy, cheaper, comfortable and effective alternative to standard dose and schedule for preventing thrombosis and infections.
引用
收藏
页码:191 / 194
页数:4
相关论文
共 23 条
[1]  
BARBATI A, 1997, ONLINE J ANESTHESIOL, V2, P1080
[2]   VERY LOW-DOSES OF WARFARIN CAN PREVENT THROMBOSIS IN CENTRAL VENOUS CATHETERS - A RANDOMIZED PROSPECTIVE TRIAL [J].
BERN, MM ;
LOKICH, JJ ;
WALLACH, SR ;
BOTHE, A ;
BENOTTI, PN ;
ARKIN, CF ;
GRECO, FA ;
HUBERMAN, M ;
MOORE, C .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :423-428
[3]   Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies [J].
Boraks, P ;
Seale, J ;
Price, J ;
Bass, G ;
Ethell, M ;
Keeling, D ;
Mahendra, P ;
Baglin, T ;
Marcus, R .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (03) :483-486
[4]  
Central Venous Access Device Guideline Panel, 2006, EV BAS SER, V16-1
[5]   Prophylactic urokinase in the management of long-term venous access devices in children: A children's oncology group study [J].
Dillon, PW ;
Jones, GR ;
Bagnall-Reeb, HA ;
Buckley, JD ;
Wiener, ES ;
Haase, GM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2718-2723
[6]  
Fan CM, 1998, SEMIN INTERVENT RAD, V15, P273
[7]  
FRASCHINI G, 1991, P AN M AM SOC CLIN, V10, P337
[8]  
Karamanoglu Ayla, 2003, J Infus Nurs, V26, P239, DOI 10.1097/00129804-200307000-00009
[9]   Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters:: final results of a double-blind, placebo-controlled phase III trial [J].
Karthaus, M ;
Kretzschmar, A ;
Kröning, H ;
Biakhov, M ;
Irwin, D ;
Marschner, N ;
Slabber, C ;
Fountzilas, G ;
Garin, A ;
Abecasis, NGF ;
Baronius, W ;
Steger, GG ;
Südhoff, T ;
Giorgetti, C ;
Reichardt, P .
ANNALS OF ONCOLOGY, 2006, 17 (02) :289-296
[10]   COMPLICATIONS AND FAILURES OF SUBCLAVIAN-VEIN CATHETERIZATION [J].
MANSFIELD, PF ;
HOHN, DC ;
FORNAGE, BD ;
GREGURICH, MA ;
OTA, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (26) :1735-1738